UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

XG005 is a non-opioid, new chemical entity with dual mode ... respectively with 1250 mg dose providing significantly more analgesia than 750 mg. Other efficacy endpoints are briefly listed below ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Over 200 adverse events were reported with a single injection of resiniferatoxin in 19 patients with refractory cancer pain. At least one adverse event occurred in all patients. Resiniferatoxin ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF ) (Innocan or th ...

Their drug TNX-102 SL* (cyclobenzaprine HCl sublingual tablets), a non-opioid investigational drug targeting fibromyalgia, which affects millions of Americans, mostly women. This type of pain ...

Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.

Duke University School of Medicine “What makes this compound exciting is that it is both analgesic and non-opioid,” said senior study author Ru-Rong Ji, an anesthesiology and neurobiology ...

In January Vertex won Food and Drug Administration approval for VX-548, Journavx® (suzetrigine) its non-opioid drug for acute pain Suzetrigine. The company now sports a market capitalization of $ ...